Q-omics provides the consensus-scored ZCRB1 profile across patient tissues and cancer cell-line models. ZCRB1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZCRB1 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, ZCRB1 protein abundance shows 22,130 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where ZCRB1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZCRB1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZCRB1 survival associations across molecular data types. ZCRB1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZCRB1 RNA expression–survival associations across cancer types. High ZCRB1 expression shows unfavorable associations in HNSC, LIHC, KIRP, KICH and LUAD, but favorable associations in OV. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZCRB1 RNA expression.
This table summarizes ZCRB1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZCRB1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZCRB1 shows higher tumor expression in HNSC, KIRC, LIHC, LUSC, KIRP and BRCA. The HNSC box plot shows higher ZCRB1 RNA expression in tumor versus normal tissue (log2 FC = +0.924, t-test p < 0.001).
This table shows molecular features associated with ZCRB1 in patient tissues and cancer cell lines. In patient samples, ZCRB1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZCRB1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and UPPER_AERODIGESTIVE_TRACT.
